title: The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
abstract: Latanoprost, a prostaglandin F2 alpha analogue prodrug, has been shown to be an effective ocular hypotensive agent when used alone on ocular hypertensive or open angle glaucoma patients. In various studies, the ocular hypotensive effects of latanoprost have also been evaluated when used in addition to, or in combination with, other ocular hypotensive agents. Latanoprost produces an additional reduction of intraocular pressure (IOP) when used in combination with timolol, pilocarpine, acetazolamide and dipivefrin. These represent four different classes of glaucoma drugs-beta-adrenergic antagonists, cholinergic agonists, carbonic anhydrase inhibitors, and adrenergic agonists-all of which reduce the IOP by different mechanisms (reduction of aqueous humor production, increased outflow facility, or by a mixed effect on aqueous humor dynamics). All the available evidence shows that latanoprost produces a clinically significant additive ocular hypotensive effect when used in combination with any currently available ocular hypotensive agent.
authors.affiliation: Department of Experimental Ophthalmology, Netherlands Ophthalmic Research Institute, Amsterdam, The Netherlands.
authors.forename: P F
authors.initials: PF
authors.lastname: Hoyng
authors.forename: A
authors.initials: A
authors.lastname: Rulo
authors.forename: E
authors.initials: E
authors.lastname: Greve
authors.forename: P
authors.initials: P
authors.lastname: Watson
authors.forename: A
authors.initials: A
authors.lastname: Alm
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000322:Adrenergic Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D018721:Muscarinic Agonists / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D010862:Pilocarpine / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*
chemical_list: D000322:Adrenergic Agonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D018721:Muscarinic Agonists; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D010862:Pilocarpine; D000077338:Latanoprost; D013999:Timolol; C015173:dipivefrin; D000086:Acetazolamide; D004837:Epinephrine